Adverse Events Associated with Disease-Modifying Drugs for Multiple Sclerosis
Neurol 102:e208006, Ng, HS.,et al, 2024
Initial Highly Effective Therapy for MS
Neurol 95:1114-1116, Wallin, M.T., 2020
Maternal and Fetal Risks of Natalizumab Exposure in Utero
Neurol 90:443-444, Marrie, R.A.,et al, 2018
Use of Newer Disease-Modifying Therapies in Pediatric Multiple Sclerosis in the US
Neurol 91:e1778-e1787, Krysko, K.M.,et al, 2018